Shares

List of FTSE 100 Pharmaceuticals and Biotechnology stocks

Following are the Pharaceutical and Bitotechnology constituents of FTSE 100 Index.

  • AstraZeneca
  • GlaxoSmithKline
  • Hikma

>> Trade on FTSE 100 Market Movements with easy markets<<

Astrazeneca

AstraZeneca(LSE:AZN) is a global, science-led Britsh-Swedish multinational biopharmaceutical business and it’s innovative medicines are used by millions of patients worldwide. AstraZeneca’s principal activities are discovering, developing, manufacturing and marketing prescription, pharmaceuticals for important areas of healthcare: cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation.

AstraZeneca, founded in 1999 through the merger of Swedish Astra AB and British Zeneca Group, has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 index, with secondary listings on the NYSE and OMX Exchange.

  • Headquarters: Cambridge, UK
  • Chairman: Leif Johansson
  • CEO: Pascal Soriot

GlaxoSmithKline

GlaxoSmithKline plc (LSE:GSK) is a British Multinational pharmaceutical company that is into research, development and manufacturing of innovative pharmaceutical medicines, vaccines and consumer healthcare products. Established in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham, has a primary listing on London Stock Exchange and has a secondary listing on NYSE. In terms of market capitalisation, GSK is considered to be the fourth largest on the London Stock Exchange.

  • Headquarters: Brentford, London
  • Chairman: Jonathan Symonds
  • CEO: Emma Walmsley

Hikma

Hikma Pharmaceuticals Plc (LSE:HIK) is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. Hikma founded in 1978 is listed on London Stock Exchange and is a constituent of the FTSE 100 Index. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 260 products in approximately 110 different dosage strengths and forms. The Company’s other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

  • Headquarters: London, UK
  • Chairman: Said Darwazah
  • CEO: Siggi Olafsson

 

Related Articles

Back to top button